Dr. Hammock is a Distinguished Professor at the University of California, Davis. Dr. Hammock was elected as a member to the National Academy of Sciences, US (1999). He has over 30 years of extensive experience in the field of eicosanoids that yielded over 800 publications and 100 issued patents on synthesis, pharmacology and biological action of eicosanoids and soluble epoxide hydrolase inhibitors.

Dr. Schmidt is head of NorthStar Consulting, LLC, which specializes in providing advice on preclinical and clinical studies of novel analgesic drugs. He is the Parliamentarian and a Past-President of the Eastern Pain Association, and has over 25 years of pharmaceutical experience specifically in the development of novel analgesic drugs. Dr. Schmidt currently sits on Scientific Advisory Boards of 1 academic laboratory and 4 biotech companies.

Dr. Giri, has extensive experience in a number of areas including pharmaceutical Research and Development, FDA relations and business development. He was VP of Research and Drug Development where he developed, pirfenidone, for treatment of pulmonary fibrosis. He later became the President and CEO of Solanan where he guided all research endeavors of the company to develop a small molecule for treating septic shock in humans.

Dr. Inceoglu is a co-founder of Eicosis. He discovered the analgesic and anti-convulsant effects of epoxygenated eicosanoids. Dr. Inceoglu served as Chief Scientific Officer at TBT Ltd, Ankara, Turkey and is a recipient of J&J Pharmaceutical’s Innovative Research Award (2008). Dr. Inceoglu has authored 40 peer reviewed publications and 4 issued patents. His research is focused on eicosanoid biology with an emphasis of neurological systems.

Mrs. McReynolds specializes in Project Management for start-up and semi-virtual biotech companies. She managed the preclinical efforts at Miikana that resulted in the identification of a small molecule IND candidate that is currently in phase 2 clinical trials. She also managed the research efforts from IND-enabling studies through Phase II clinical trials at Arete Therapeutics.

Dr. Buckpitt is a Professor at the University of Califorania, Davis. Dr. Buckpitt currently specializes in pharmacokinetics, and absorption, distribution, metabolism, and excretion as well as site selective toxicity of the lung and kidney.

Dr. Wagner is a post doctoral scholar at the University of California Davis. Dr. Wagner received her Ph.D. in Pharmacology and Toxicology from the University of Califorina Davis in 2012. She then served as a Ruth L. Kirschstein National Research Service Award Postdoctoral Fellow. She has numerous peer reviewed publications investigating pain and therapeutics. Her research focus is on neurobiology and eicosanoids.

Dr. Buckpitt is a Professor at the University of Califorania, Davis. Dr. Buckpitt currently specializes in pharmacokinetics, and absorption, distribution, metabolism, and excretion as well as site selective toxicity of the lung and kidney.